CANbridge Pharmaceuticals Inc. announced that data on a novel second-generation spinal muscular atrophy gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, was presented as a poster at the American Society of Gene and Cell Therapy 26th Annual Meeting, in Los Angeles.
